{"id":36818,"date":"2025-07-07T14:04:38","date_gmt":"2025-07-07T06:04:38","guid":{"rendered":"https:\/\/flcube.com\/?p=36818"},"modified":"2025-07-07T14:04:39","modified_gmt":"2025-07-07T06:04:39","slug":"astrazenecas-imfinzi-approved-in-eu-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36818","title":{"rendered":"AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer"},"content":{"rendered":"\n

UK-based AstraZeneca (AZ, NASDAQ: AZN<\/a>) announced that it has received marketing approval in the European Union (EU) for Imfinzi (durvalumab). This approval makes Imfinzi the first and only immunotherapy for the perioperative treatment of resectable muscle-invasive bladder cancer (MIBC) in the region. The regimen involves combining neoadjuvant Imfinzi with gemcitabine and cisplatin before surgery, followed by adjuvant Imfinzi monotherapy post-operation.<\/p>\n\n\n\n

Clinical Trial Results<\/strong>
The approval is based on results from the Phase III NIAGARA study. The study demonstrated that the Imfinzi regimen significantly improved event-free survival (EFS) compared to the neoadjuvant chemotherapy group alone, reducing the risk of disease recurrence or death by 32%. The two-year EFS rate was 67.8% for the Imfinzi group, compared to 59.8% in the control group. The overall tolerability was good, with no new safety signals observed.<\/p>\n\n\n\n

Mechanism of Action<\/strong>
Imfinzi is a PD-L1-blocking monoclonal antibody that disrupts tumor immune evasion by inhibiting PD-L1 interactions with PD-1\/CD80. The drug is already approved for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, and biliary tract cancer. This approval further expands its application into perioperative and combination immunotherapy across various malignancies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European…<\/p>\n","protected":false},"author":1,"featured_media":36820,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[770,16,871,18,15],"class_list":["post-36818","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-az","tag-cancer","tag-nasdaq-azn","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"\nAstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European Union (EU) for Imfinzi (durvalumab). This approval makes Imfinzi the first and only immunotherapy for the perioperative treatment of resectable muscle-invasive bladder cancer (MIBC) in the region. The regimen involves combining neoadjuvant Imfinzi with gemcitabine and cisplatin before surgery, followed by adjuvant Imfinzi monotherapy post-operation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36818\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer\" \/>\n<meta property=\"og:description\" content=\"UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European Union (EU) for Imfinzi (durvalumab). This approval makes Imfinzi the first and only immunotherapy for the perioperative treatment of resectable muscle-invasive bladder cancer (MIBC) in the region. The regimen involves combining neoadjuvant Imfinzi with gemcitabine and cisplatin before surgery, followed by adjuvant Imfinzi monotherapy post-operation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36818\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T06:04:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-07T06:04:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer\",\"datePublished\":\"2025-07-07T06:04:38+00:00\",\"dateModified\":\"2025-07-07T06:04:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818\"},\"wordCount\":205,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0705.webp\",\"keywords\":[\"AZ\",\"Cancer\",\"NASDAQ: AZN\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36818#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36818\",\"name\":\"AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0705.webp\",\"datePublished\":\"2025-07-07T06:04:38+00:00\",\"dateModified\":\"2025-07-07T06:04:39+00:00\",\"description\":\"UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European Union (EU) for Imfinzi (durvalumab). This approval makes Imfinzi the first and only immunotherapy for the perioperative treatment of resectable muscle-invasive bladder cancer (MIBC) in the region. The regimen involves combining neoadjuvant Imfinzi with gemcitabine and cisplatin before surgery, followed by adjuvant Imfinzi monotherapy post-operation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36818\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0705.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36818#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer - Insight, China's Pharmaceutical Industry","description":"UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European Union (EU) for Imfinzi (durvalumab). This approval makes Imfinzi the first and only immunotherapy for the perioperative treatment of resectable muscle-invasive bladder cancer (MIBC) in the region. The regimen involves combining neoadjuvant Imfinzi with gemcitabine and cisplatin before surgery, followed by adjuvant Imfinzi monotherapy post-operation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36818","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer","og_description":"UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European Union (EU) for Imfinzi (durvalumab). This approval makes Imfinzi the first and only immunotherapy for the perioperative treatment of resectable muscle-invasive bladder cancer (MIBC) in the region. The regimen involves combining neoadjuvant Imfinzi with gemcitabine and cisplatin before surgery, followed by adjuvant Imfinzi monotherapy post-operation.","og_url":"https:\/\/flcube.com\/?p=36818","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-07T06:04:38+00:00","article_modified_time":"2025-07-07T06:04:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36818#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36818"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer","datePublished":"2025-07-07T06:04:38+00:00","dateModified":"2025-07-07T06:04:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36818"},"wordCount":205,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36818#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0705.webp","keywords":["AZ","Cancer","NASDAQ: AZN","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36818#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36818","url":"https:\/\/flcube.com\/?p=36818","name":"AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36818#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36818#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0705.webp","datePublished":"2025-07-07T06:04:38+00:00","dateModified":"2025-07-07T06:04:39+00:00","description":"UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European Union (EU) for Imfinzi (durvalumab). This approval makes Imfinzi the first and only immunotherapy for the perioperative treatment of resectable muscle-invasive bladder cancer (MIBC) in the region. The regimen involves combining neoadjuvant Imfinzi with gemcitabine and cisplatin before surgery, followed by adjuvant Imfinzi monotherapy post-operation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36818#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36818"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36818#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0705.webp","width":1080,"height":608,"caption":"AstraZeneca's Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36818#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0705.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36818"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36818\/revisions"}],"predecessor-version":[{"id":36821,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36818\/revisions\/36821"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36820"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}